Chikungunya vaccine shows promise for Long-Term protection
NCT ID NCT04838444
First seen Jun 27, 2026 · Last updated Jul 10, 2026 · Updated 2 times
Summary
This Phase 3 trial follows adults who previously received the VLA1553 chikungunya vaccine to see how long their antibodies last and to monitor long-term safety. About 363 participants are being tracked for up to several years. The goal is to determine if a single shot can provide durable immunity against the virus.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- VLA1553 (live-attenuated chikungunya virus vaccine)
- What this could lead to
- If successful, this could confirm that a single dose of the vaccine provides long-lasting protection against chikungunya.
- What could go wrong
- This is an open-label, single-arm study with no placebo group, so results may be less definitive. Long-term safety data are still being collected.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHIKUNGUNYA VIRUS INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Accelerated Enrollment Solutions (AES)
Phoenix, Arizona, 85020, United States
-
Accelerated Enrollment Solutions (AES)
Chicago, Illinois, 60602, United States
-
Alliance for Multispecialty Research (AMR)
Lexington, Kentucky, 40509, United States
-
Alliance for Multispecialty Research (AMR)
Knoxville, Tennessee, 37920, United States
-
Allliance for Multispecialty Research (AMR)
Norfolk, Virginia, 23502, United States
-
Velocity Clinical Research
Hallandale, Florida, 33090, United States
-
Velocity Clinical Research
Grand Island, Nebraska, 68803, United States
-
Velocity Clinical Research
Omaha, Nebraska, 68134, United States
-
Velocity Clinical Research
Austin, Texas, 78759, United States
-
Velocity Clinical Research
West Jordan, Utah, 84088, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New rapid test could speed up tropical fever diagnosis
- Chikungunya vaccine safety checked in pregnant women
- New chikungunya vaccine enters first human safety trial
- Brazilian pilot program tests chikungunya Vaccine's Real-World power
- 5,000 volunteers tracked to see if chikungunya vaccine is safe
- Early safety check for new chikungunya drug